



INSTITUTE FOR ANIMAL HEALTH
Director: Professor Martin W. Shirley, PhD
PIRBRIGHT LABORATORY
Ash Road,
Pirbright,
Surrey,
GU24 0NF
Intn Tel: 00 44 1483 232441
Tel: 01483 232441 Fax: 01483 232621

FMD Vaccine Matching Strain Differentiation Report

Lab Reference WRL Batch Number: WRLFMD/2009/00029

Sender Details:

[REDACTED]

Date Received: 2nd June 2009

Country of Origin: Israel

Date Reported: 15th September 2009

Results A

[REDACTED]

Official Stamp:

[REDACTED]

Date:

18/9/09

[REDACTED]

To help us improve the quality of our service, please send any suggestions or requests to the Reference Laboratory by fax (+44 (0) 1483 232621 or email: elizabeth.byrom@bbsrc.ac.uk)

Report no:	VNT				LPBE					
	VNT	O Manisa	O Bfs	O Ind R2/75	ELISA	O 4174	O BFS 1860	O 4625	O 3039	O Manisa
O Isr 43/2007	mean	0.36	0.17	>0.74	mean	0.18	0.10	0.50	0.84	0.63
O Isr 50/2007	mean	0.21	0.20	>1.0	mean	0.25	0.18	0.32	0.33	0.44
O Isr 1/2008	mean				mean		0.05		0.11	

Interpretation of Results

In the case of Virus Neutralisation Test (VNT):

$r_1 = \geq 0.3$. Suggests that there is a close relationship between field isolate and vaccine strain. A potent vaccine containing the vaccine strain is likely to confer protection.

$r_1 = < 0.3$. Suggests that the field isolate is so different from the vaccine strain that the vaccine is unlikely to protect

In the case of Liquid Phase Blocking Elisa (LPBE):

$r_1 = 0.4-1.0$. Suggests that there is a close relationship between field isolate and vaccine strain. A potent vaccine containing the vaccine strain is likely to confer protection.

$r_1 = 0.2-0.39$, Suggests that the field isolate is antigenically related to the vaccine strain. The vaccine strain might be suitable for use if no closer match can be found provided that a potent vaccine is used and animals are preferably immunised more than once.

$r_1 = < 0.2$. Suggests that the field isolate is so different from the vaccine strain that the vaccine is unlikely to protect.